6月4日 - ** Fulcrum Therapeutics FULC.O 股价在盘后交易中下跌3%，至3.27美元
** FULC在停止开发用于治疗镰状细胞病的pociredir (link) 药物后，批准了重组计划
** 因美国FDA提出癌症风险担忧，Fulcrum放弃了该药物的研发
** 公司计划裁员85%，员工人数将从57人缩减至9人，预计第二季度完成
** 预计第二季度将产生约420万美元的重组费用
** FULC 股票今年以来累计下跌70%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.